A new class of drugs, including JAK inhibitors and biologics, is showing significant promise in treating Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition that affects an estimated one in every 100 Britons. The condition causes painful, boil-like lumps to form deep under the skin, typically in areas like the armpits and groin, often stemming from blocked hair follicles.
For many years, treatment options for HS were limited to antibiotics, antibacterial washes, and pain relief. However, these methods often fail to fully clear outbreaks or prevent their recurrence, especially in severe cases. Experts now suggest that JAK inhibitors, already used for conditions such as rheumatoid arthritis and eczema, could target the underlying inflammation driving HS at a cellular level. While these medications cannot reverse advanced skin damage, they may be a "gamechanger" for early or milder cases.
Dr. Abirami Pararajasingam, a consultant dermatologist and British Skin Foundation spokesman, noted that the U.S. is generally more proactive in providing patients with these drugs due to fewer intervention restrictions. In contrast, she highlighted pricing issues in the UK that hinder patient access, emphasizing that early intervention is crucial as chronic inflammation associated with HS can increase the risk of other long-term health problems, including heart disease and stroke.
More than 700,000 Britons are now estimated to have HS. The disease, once thought rare, is caused by an overactive immune system triggering an abnormal inflammatory response when hair follicles become blocked. Symptoms can range from small, self-resolving lumps to open, slow-healing wounds that cause extensive scarring. Women are more commonly affected, with symptoms often beginning in adolescence. Due to its varied presentation and lack of a definitive diagnostic test, HS can take up to ten years to diagnose in the UK, leaving many patients unaware of their condition and coping with its progression.
Factors contributing to HS include genetics, being overweight or obese, and smoking. Nicotine and other tobacco chemicals can thicken skin and block follicles, while excess body fat releases pro-inflammatory chemicals. However, some individuals are predisposed due to their hair follicle and oil gland structure.
Recent advancements include biologics, a class of drugs that target and block specific immune system proteins responsible for inflammation and tissue damage, thereby reducing flare-ups. Laurelle-Maria Sterling, who has lived with HS since her teens, found that the biologic drug adalimumab, used for conditions like rheumatoid arthritis, significantly calmed her inflammation, leading to less severe flare-ups after years of ineffective antibiotic treatments.
In the U.S., adalimumab and JAK inhibitors are already utilized for milder HS cases. Research published in Nature indicated that the JAK inhibitor povorcitinib reduced inflammatory nodules and abscesses by over 50 percent in HS patients. Dr. Beibei Du-Harpur, a clinical lecturer in dermatology at King's College London, anticipates that these promising JAK inhibitor drugs will be rolled out by the NHS for HS patients within the next one to two years. She also stressed the need to raise awareness among both patients and clinicians, as early diagnosis and treatment can prevent significant damage.